"10.1371_journal.pone.0072238","plos one","2013-08-19T00:00:00Z","Daria Y Alakhova; Yi Zhao; Shu Li; Alexander V Kabanov","Center for Drug Delivery and Nanomedicine and Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, United States of America; Laboratory of Chemical Design of Bionanomaterials, Faculty of Chemistry, M.V. Lomonosov Moscow State University, Moscow, Russia","Conceived and designed the experiments: DA YZ AK. Performed the experiments: DA YZ SL. Analyzed the data: DA YZ. Contributed reagents/materials/analysis tools: AK. Wrote the paper: DA YZ AK.","AVK is a co-founder of Supratek Pharma, Inc. He is a minority shareholder, chairman of the scientific advisory board and a member of the board of directors of Supratek Pharma, Inc. Supratek Pharma, Inc. develops SP1049C for treatment of cancer. SP1049C is held under the following patents: (1) Klinski et al., Doxorubicin formulations for anti-cancer use, United States Patent 8148338, Apr 3, 2012; (2) Kabanov et al., Polymer compositions for chemotherapy and methods of treatment using the same, United States Patent 6,060,518, May 9, 2000; (3) Alakhov et al., Biological agent compositions, United States Patent 5,817,321, Oct 6, 1998. SP1049C, a formulation of doxorubicin (Dox) with mixed micelles of Pluronics L61 and F127 was kindly provided by Supratek Pharma, Inc. (Montreal, Canada). There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","08","Daria Y Alakhova","DYA",4,TRUE,3,3,2,3,TRUE,TRUE,FALSE,0,NA,FALSE
